Assessing the potential impact of COVID-19 on life expectancy.
Adult
Africa South of the Sahara
/ epidemiology
Age Distribution
Aged
Americas
/ epidemiology
Asia
/ epidemiology
Betacoronavirus
COVID-19
Computer Simulation
Coronavirus Infections
/ mortality
Developing Countries
Europe
/ epidemiology
Female
Global Health
Humans
Life Expectancy
Male
Middle Aged
Models, Theoretical
Pandemics
Pneumonia, Viral
/ mortality
Prevalence
SARS-CoV-2
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
05
2020
accepted:
22
08
2020
entrez:
17
9
2020
pubmed:
18
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
The COVID-19 virus pandemic has caused a significant number of deaths worldwide. If the prevalence of the infection continues to grow, this could impact life expectancy. This paper provides first estimates of the potential direct impact of the COVID-19 pandemic on period life expectancy. From the estimates of bias-adjusted age-specific infection fatality rates in Hubei (China) and a range of six prevalence rate assumptions ranging from 1% to 70%, we built a discrete-time microsimulation model that simulates the number of people infected by COVID-19, the number dying from it, and the number of deaths from all causes week by week for a period of one year. We applied our simulation to four broad regions: North America and Europe; Latin America and the Caribbean; Southeastern Asia; and sub-Saharan African. For each region, 100,000 individuals per each 5-year age group are simulated. At a 10% COVID-19 prevalence rate, the loss in life expectancy at birth is likely above 1 year in North America and Europe and in Latin America and the Caribbean. In Southeastern Asia and sub-Saharan Africa, one year lost in life expectancy corresponds to an infection prevalence of about 15% and 25%, respectively. Given the uncertainty in fatality rates, with a 50% prevalence of COVID-19 infections under 95% prediction intervals, life expectancy would drop by 3 to 9 years in North America and Europe, by 3 to 8 years in Latin America and the Caribbean, by 2 to 7 years in Southeastern Asia, and by 1 to 4 years in sub-Saharan Africa. In all prevalence scenarios, as long as the COVID-19 infection prevalence rate remains below 1 or 2%, COVID-19 would not affect life expectancy in a substantial manner. In regions with relatively high life expectancy, if the infection prevalence threshold exceeds 1 or 2%, the COVID-19 pandemic will break the secular trend of increasing life expectancy, resulting in a decline in period life expectancy. With life expectancy being a key indicator of human development, mortality increase, especially among the vulnerable subgroups of populations, would set a country back on its path of human development.
Sections du résumé
BACKGROUND
The COVID-19 virus pandemic has caused a significant number of deaths worldwide. If the prevalence of the infection continues to grow, this could impact life expectancy. This paper provides first estimates of the potential direct impact of the COVID-19 pandemic on period life expectancy.
METHODS
From the estimates of bias-adjusted age-specific infection fatality rates in Hubei (China) and a range of six prevalence rate assumptions ranging from 1% to 70%, we built a discrete-time microsimulation model that simulates the number of people infected by COVID-19, the number dying from it, and the number of deaths from all causes week by week for a period of one year. We applied our simulation to four broad regions: North America and Europe; Latin America and the Caribbean; Southeastern Asia; and sub-Saharan African. For each region, 100,000 individuals per each 5-year age group are simulated.
RESULTS
At a 10% COVID-19 prevalence rate, the loss in life expectancy at birth is likely above 1 year in North America and Europe and in Latin America and the Caribbean. In Southeastern Asia and sub-Saharan Africa, one year lost in life expectancy corresponds to an infection prevalence of about 15% and 25%, respectively. Given the uncertainty in fatality rates, with a 50% prevalence of COVID-19 infections under 95% prediction intervals, life expectancy would drop by 3 to 9 years in North America and Europe, by 3 to 8 years in Latin America and the Caribbean, by 2 to 7 years in Southeastern Asia, and by 1 to 4 years in sub-Saharan Africa. In all prevalence scenarios, as long as the COVID-19 infection prevalence rate remains below 1 or 2%, COVID-19 would not affect life expectancy in a substantial manner.
INTERPRETATION
In regions with relatively high life expectancy, if the infection prevalence threshold exceeds 1 or 2%, the COVID-19 pandemic will break the secular trend of increasing life expectancy, resulting in a decline in period life expectancy. With life expectancy being a key indicator of human development, mortality increase, especially among the vulnerable subgroups of populations, would set a country back on its path of human development.
Identifiants
pubmed: 32941467
doi: 10.1371/journal.pone.0238678
pii: PONE-D-20-14391
pmc: PMC7498023
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0238678Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Disaster Med Public Health Prep. 2020 Oct;14(5):643-647
pubmed: 32228732
J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
J Prev Med Public Health. 2020 May;53(3):151-157
pubmed: 32498136
Lancet Glob Health. 2020 Apr;8(4):e480
pubmed: 32109372
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Epidemiol. 2020 Jun 1;49(3):717-726
pubmed: 32086938
Proc Natl Acad Sci U S A. 2020 May 5;117(18):9696-9698
pubmed: 32300018
Clin Med (Lond). 2020 Mar;20(2):124-127
pubmed: 32139372
BMJ Open. 2021 Mar 10;11(3):e042934
pubmed: 33692179
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
PLoS Curr. 2015 Feb 19;7:
pubmed: 25737805
Nat Med. 2020 Jul;26(7):986-988
pubmed: 32439872
PLoS One. 2020 Nov 5;15(11):e0241952
pubmed: 33152009
Acta Biomed. 2020 Apr 10;91(3-S):175-179
pubmed: 32275287
J Clin Med. 2020 Mar 31;9(4):
pubmed: 32244365
Popul Dev Rev. 2000;26(3):565-81
pubmed: 19530360
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
BMJ. 2020 Apr 2;369:m1375
pubmed: 32241884
Lancet Public Health. 2020 Jun;5(6):e310
pubmed: 32339478
J Travel Med. 2020 Mar 13;27(2):
pubmed: 32052846
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet Glob Health. 2020 Jul;8(7):e901-e908
pubmed: 32405459
Lancet Glob Health. 2020 May;8(5):e641-e642
pubmed: 32199072
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748